Escherichia coli in Europe: An overview

International Journal of Environmental Research and Public Health

Volumn 10, Issue 12, 2013, Pages 6235-6254

  Allocati, Nerino ^a   Masulli, Michele ^a   Alexeyev, Mikhail F ^b   Di Ilio, Carmine ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Antimicrobial peptides; Combination therapy; Epidemiology; Escherichia coli; Gram negative bacteria; Multidrug resistance; Pathotype; Phage therapy

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; NALIDIXIC ACID; PENICILLIN DERIVATIVE; PENICILLIN G; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; WATER;

ANTIMICROBIAL ACTIVITY; COLIFORM BACTERIUM; EPIDEMIOLOGY; INFECTIOUS DISEASE; PATHOTYPE; PEPTIDE;

ADHERENT INVASIVE ESCHERICHIA COLI; ANTIBIOTIC RESISTANCE; ARMA GENE; AVIAN PATHOGENIC ESCHERICHIA COLI; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIOPHAGE; BIFIDOBACTERIUM; CHROMOSOME ANALYSIS; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DIARRHEA; DIFFUSELY ADHERENT ESCHERICHIA COLI; EFFUSION; ENTERITIS; ENTEROAGGREGATIVE ESCHERICHIA COLI; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ENTEROINVASIVE ESCHERICHIA COLI; ENTEROPATHOGENIC ESCHERICHIA COLI; ENTEROTOXIGENIC ESCHERICHIA COLI; ENVIRONMENTAL SANITATION; ENZYME INACTIVATION; EPIDEMIC; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; EUROPE; FOOD HANDLING; FOOD SAFETY; GASTROINTESTINAL INFECTION; HEALTH EDUCATION; HUMAN; INFECTION CONTROL; LACTOBACILLUS; MOLECULAR EPIDEMIOLOGY; MONOTHERAPY; NEONATAL MENINGITIS ESCHERICHIA COLI; NONHUMAN; PREVALENCE; PUBLIC HEALTH; REVIEW; RISK REDUCTION; RNA METHYLATION; SYMPTOMATOLOGY; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI; VACCINATION; VAGINITIS; WATER QUALITY;

EUROPE;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; NEGIBACTERIA;

ANIMALS; ANTI-INFECTIVE AGENTS; BIOLOGICAL WARFARE AGENTS; DISEASE OUTBREAKS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; EUROPE; HUMANS;

EID: 84888366154     PISSN: 16617827     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph10126235     Document Type: Review

References (127)

1. Kaper, J. B.; Nataro, J. P.; Mobley, H. L. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2004, 2, 123-140.
2. Yoo, S. H.; Jeong, H.; Kwon, S.-K.; Kim, J. F. Genomics, Biological Features, and Biotechnological Applications of Escherichia coli B: Is B for better; Springer: Berlin, Germany, 2009.
3. Bilinski, P.; Kapka-Skrzypczak, L.; Posobkiewicz, M.; Bondaryk, M.; Holownia, P.; Wojtyla, A. Public health hazards in Poland posed by foodstuffs contaminated with E. coli O104: H4 bacterium from the recent European outbreak. Ann. Agric. Environ. Med. 2012, 19, 3-10.
4. Qadri, F.; Svennerholm, A. M.; Faruque, A. S.; Sack, R. B. Enterotoxigenic Escherichia coli in developing countries: Epidemiology, microbiology, clinical features, treatment, and prevention. Clin. Microbiol. Rev. 2005, 18, 465-483.
5. Al-Abri, S. S.; Beeching, N. J.; Nye, F. J. Traveller's diarrhoea. Lancet Infect. Dis. 2005, 5, 349-360.
6. Weintraub, A. Enteroaggregative Escherichia coli: Epidemiology, virulence and detection. J. Med. Microbiol. 2007, 56, 4-8.
7. Nataro, J. P.; Steiner, T.; Guerrant, R. L. Enteroaggregative Escherichia coli. Emerg. Infect. Dis. 1998, 4, 251-261.
8. Servin, A. L. Pathogenesis of Afa/Dr diffusely adhering Escherichia coli. Clin. Microbiol. Rev. 2005, 18, 264-292.
9. Darfeuille-Michaud, A. Adherent-invasive Escherichia coli: A putative new E. coli pathotype associated with Crohn's disease. Int. J. Med. Microbiol. 2002, 292, 185-193.
10. Negroni, A.; Costanzo, M.; Vitali, R.; Superti, F.; Bertuccini, L.; Tinari, A.; Minelli, F.; di Nardo, G.; Nuti, F.; Pierdomenico, M.; et al. Characterization of adherent-invasive Escherichia coli isolated from pediatric patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2012, 18, 913-924.
11. Johnson, J. R.; Stell, A. L. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J. Infect. Dis. 2000, 181, 261-272.
12. Gaschignard, J.; Levy, C.; Romain, O.; Cohen, R.; Bingen, E.; Aujard, Y.; Boileau, P. Neonatal bacterial meningitis: 444 cases in 7 years. Pediatr. Infect. Dis. J. 2011, 30, 212-217.
13. Pouillot, F.; Chomton, M.; Blois, H.; Courroux, C.; Noelig, J.; Bidet, P.; Bingen, E.; Bonacorsi, S. Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b: H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob. Agents Chemother. 2012, 56, 3568-3575.
14. Johnson, T. J.; Kariyawasam, S.; Wannemuehler, Y.; Mangiamele, P.; Johnson, S. J.; Doetkott, C.; Skyberg, J. A.; Lynne, A. M.; Johnson, J. R.; Nolan, L. K. The genome sequence of avian pathogenic Escherichia coli strain O1: K1: H7 shares strong similarities with human extraintestinal pathogenic E. coli genomes. J. Bacteriol. 2007, 189, 3228-3236.
15. Rodriguez-Siek, K. E.; Giddings, C. W.; Doetkott, C.; Johnson, T. J.; Fakhr, M. K.; Nolan, L. K. Comparison of Escherichia coli isolates implicated in human urinary tract infection and avian colibacillosis. Microbiology 2005, 151, 2097-2110.
16. Tivendale, K. A.; Logue, C. M.; Kariyawasam, S.; Jordan, D.; Hussein, A.; Li, G.; Wannemuehler, Y.; Nolan, L. K. Avian-pathogenic Escherichia coli strains are similar to neonatal meningitis E. coli strains and are able to cause meningitis in the rat model of human disease. Infect. Immun. 2010, 78, 3412-3419.
17. The Evolving Threat of Antimicrobial Resistance: Options for Action; World Health Organization: Geneva, Switzerland, 2012.
18. Von Baum, H.; Marre, R. Antimicrobial resistance of Escherichia coli and therapeutic implications. Int. J. Med. Microbiol. 2005, 295, 503-511.
19. Van der Bij, A. K.; Pitout, J. D. The role of international travel in the worldwide spread of multiresistant Enterobacteriaceae. J. Antimicrob. Chemother. 2012, 67, 2090-2100.
20. Szmolka, A.; Nagy, B. Multidrug resistant commensal Escherichia coli in animals and its impact for public health. Front. Microbiol. 2013, 4, 258, doi: 10. 3389/fmicb. 2013. 00258.
21. Magiorakos, A. P.; Srinivasan, A.; Carey, R. B.; Carmeli, Y.; Falagas, M. E.; Giske, C. G.; Harbarth, S.; Hindler, J. F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012, 18, 268-281.
22. Johnson, T. J.; Nolan, L. K. Pathogenomics of the virulence plasmids of Escherichia coli. Microbiol. Mol. Biol. Rev. 2009, 73, 750-774.
23. Johnson, T. J.; Logue, C. M.; Johnson, J. R.; Kuskowski, M. A.; Sherwood, J. S.; Barnes, H. J.; DebRoy, C.; Wannemuehler, Y. M.; Obata-Yasuoka, M.; Spanjaard, L.; et al. Associations between multidrug resistance, plasmid content, and virulence potential among extraintestinal pathogenic and commensal Escherichia coli from humans and poultry. Foodborne Pathog. Dis. 2012, 9, 37-46.
24. Erb, A.; Sturmer, T.; Marre, R.; Brenner, H. Prevalence of antibiotic resistance in Escherichia coli: Overview of geographical, temporal, and methodological variations. Eur. J. Clin. Microbiol. Infect. Dis. 2007, 26, 83-90.
25. European Centre for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe 2011; Annual Report of the European Antimicrobial Resistance Surveillance Network: Stockholm, Sweden, 2012.
26. Critically Important Antimicrobials for Human Medicine: Categorization for the Development of Risk Management Strategies to Contain Antimicrobial Resistance due to Non-Human Antimicrobial Use. In Proccedings of Report of the 2nd WHO Expert Meeting, Copenhagen, Danmark, 29-31 May 2007.
27. Poirel, L.; Bonnin, R. A.; Nordmann, P. Genetic support and diversity of acquired extended-spectrum beta-lactamases in Gram-negative rods. Infect. Genet. Evol. 2012, 12, 883-893.
28. Canton, R.; Coque, T. M. The CTX-M beta-lactamase pandemic. Curr. Opin. Microbiol. 2006, 9, 466-475.
29. Livermore, D. M.; Canton, R.; Gniadkowski, M.; Nordmann, P.; Rossolini, G. M.; Arlet, G.; Ayala, J.; Coque, T. M.; Kern-Zdanowicz, I.; Luzzaro, F.; et al. CTX-M: Changing the face of ESBLs in Europe. J. Antimicrob. Chemother. 2007, 59, 165-174.
30. Lopez-Cerero, L.; Bellido, M. D.; Serrano, L.; Liro, J.; Cisneros, J. M.; Rodriguez-Bano, J.; Pascual, A. Escherichia coli O25b: H4/ST131 are prevalent in Spain and are often not associated with ESBL or quinolone resistance. Enferm. Infecc. Microbiol. Clin. 2013, 31, 385-388.
31. Rogers, B. A.; Sidjabat, H. E.; Paterson, D. L. Escherichia coli O25b-ST131: A pandemic, multiresistant, community-associated strain. J. Antimicrob. Chemother. 2011, 66, 1-14.
32. Walsh, F.; Rogers, T. R. Comparison of plasmid-mediated quinolone resistance and extended-spectrum beta-lactamases in third-generation cephalosporin-resistant Enterobacteriaceae from four Irish hospitals. J. Med. Microbiol. 2012, 61, 142-147.
33. Mugnaioli, C.; Luzzaro, F.; de Luca, F.; Brigante, G.; Perilli, M.; Amicosante, G.; Stefani, S.; Toniolo, A.; Rossolini, G. M. CTX-M-type extended-spectrum beta-lactamases in Italy: Molecular epidemiology of an emerging countrywide problem. Antimicrob. Agents Chemother. 2006, 50, 2700-2706.
34. Ewers, C.; Bethe, A.; Semmler, T.; Guenther, S.; Wieler, L. H. Extended-spectrum beta-lactamase-producing and AmpC-producing Escherichia coli from livestock and companion animals, and their putative impact on public health: A global perspective. Clin. Microbiol. Infect. 2012, 18, 646-655.
35. Queenan, A. M.; Bush, K. Carbapenemases: The versatile beta-lactamases. Clin. Microbiol. Rev. 2007, 20, 440-458.
36. Canton, R.; Akova, M.; Carmeli, Y.; Giske, C. G.; Glupczynski, Y.; Gniadkowski, M.; Livermore, D. M.; Miriagou, V.; Naas, T.; Rossolini, G. M.; et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 2012, 18, 413-431.
37. Shevchenko, O. V.; Mudrak, D. Y.; Skleenova, E. Y.; Kozyreva, V. K.; Ilina, E. N.; Ikryannikova, L. N.; Alexandrova, I. A.; Sidorenko, S. V.; Edelstein, M. V. First detection of VIM-4 metallo-beta-lactamase-producing Escherichia coli in Russia. Clin. Microbiol. Infect. 2012, 18, E214-E217.
38. Nordmann, P.; Naas, T.; Poirel, L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 2011, 17, 1791-1798.
39. Mushtaq, S.; Irfan, S.; Sarma, J. B.; Doumith, M.; Pike, R.; Pitout, J.; Livermore, D. M.; Woodford, N. Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J. Antimicrob. Chemother. 2011, 66, 2002-2005.
40. Glasner, C.; Albiger, B.; Buist, G.; Tambic Andrasevic, A.; Canton, R.; Carmeli, Y.; Friedrich, A.; Giske, C.; Glupczynski, Y.; Gniadkowski, M.; et al. Carbapenemase-producing Enterobacteriaceae in Europe: A survey among national experts from 39 countries, February 2013. Euro Surveill. 2013, 18. Available online: http: //www. eurosurveillance. org/View Article. aspx?ArticleId=20525 (accessed on 5 November 2013).
41. Hopkins, K. L.; Davies, R. H.; Threlfall, E. J. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: Recent developments. Int. J. Antimicrob. Agents 2005, 25, 358-373.
42. Hooper, D. C. Mechanisms of fluoroquinolone resistance. Drug Resist. Updats 1999, 2, 38-55.
43. Ruiz, J.; Pons, M. J.; Gomes, C. Transferable mechanisms of quinolone resistance. Int. J. Antimicrob. Agents 2012, 40, 196-203.
44. Robicsek, A.; Jacoby, G. A.; Hooper, D. C. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect. Dis. 2006, 6, 629-640.
45. Schito, G. C.; Naber, K. G.; Botto, H.; Palou, J.; Mazzei, T.; Gualco, L.; Marchese, A. The ARESC study: An international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int. J. Antimicrob. Agents 2009, 34, 407-413.
46. Schultsz, C.; Geerlings, S. Plasmid-mediated resistance in Enterobacteriaceae: Changing landscape and implications for therapy. Drugs 2012, 72, 1-16.
47. Över, U.; Gur, D.; Ünal, S.; Miller, G. H.; Aminoglycoside Resistance Study Group. The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey. Clin. Microbiol. Infect. 2001, 7, 470-478.
48. Zarubica, T.; Baker, M. R.; Wright, H. T.; Rife, J. P. The aminoglycoside resistance methyltransferases from the ArmA/Rmt family operate late in the 30S ribosomal biogenesis pathway. RNA 2011, 17, 346-355.
49. Lindemann, P. C.; Risberg, K.; Wiker, H. G.; Mylvaganam, H. Aminoglycoside resistance in clinical Escherichia coli and Klebsiella pneumoniae isolates from western Norway. APMIS 2012, 120, 495-502.
50. Livermore, D. M.; Mushtaq, S.; Warner, M.; Zhang, J. C.; Maharjan, S.; Doumith, M.; Woodford, N. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J. Antimicrob. Chemother. 2011, 66, 48-53.
51. Galimand, M.; Sabtcheva, S.; Courvalin, P.; Lambert, T. Worldwide disseminated armA aminoglycoside resistance methylase gene is borne by composite transposon Tn1548. Antimicrob. Agents Chemother. 2005, 49, 2949-2953.
52. Van Duijn, P. J.; Dautzenberg, M. J.; Oostdijk, E. A. Recent trends in antibiotic resistance in European ICUs. Curr. Opin. Crit. Care 2011, 17, 658-665.
53. Kronvall, G. Antimicrobial resistance 1979-2009 at Karolinska hospital, Sweden: Normalized resistance interpretation during a 30-year follow-up on Staphylococcus aureus and Escherichia coli resistance development. APMIS 2010, 118, 621-639.
54. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2012; Reporting on 2010 Surveillance Data and 2011 Epidemic Intelligence Data: Stockholm, Sweden, 2013.
55. Thorsteinsdottir, T. R.; Haraldsson, G.; Fridriksdottir, V.; Kristinsson, K. G.; Gunnarsson, E. Prevalence and genetic relatedness of antimicrobial-resistant Escherichia coli isolated from animals, foods and humans in Iceland. Zoonoses Public Health 2010, 57, 189-196.
56. Priamchuk, S. D.; Fursova, N. K.; Abaev, I. V.; Kovalev Iu, N.; Shishkova, N. A.; Pecherskikh, E. I.; Korobova, O. V.; Astashkin, E. I.; Pachkunov, D. M.; Kruglov, A. N.; et al. Genetic determinants of antibacterial resistance among nosocomial Escherichia coli, Klebsiella spp., and Enterobacter spp. isolates collected in Russia within 2003-2007. Antibiot. Khimioter. 2010, 55, 3-10.
57. European Antimicrobial Resistance Surveillance System. EARSS Annual Report 2008; EARSS: Bilthoven, The Netherland, 2009.
58. Tonkic, M.; Goic-Barisic, I.; Punda-Polic, V. Prevalence and antimicrobial resistance of extended-spectrum beta-lactamases-producing Escherichia coli and Klebsiella pneumoniae strains isolated in a university hospital in Split, Croatia. Int. Microbiol. 2005, 8, 119-124.
59. Balode, A.; Punda-Polic, V.; Dowzicky, M. J. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in eastern Europe: Results from the Tigecycline Evaluation and Surveillance Trial (T. E. S. T.) 2004-2010. Int. J. Antimicrob. Agents 2013, 41, 527-535.
60. Pitout, J. D. Multiresistant Enterobacteriaceae: New threat of an old problem. Expert Rev. Anti Infect. Ther. 2008, 6, 657-669.
61. Pitout, J. D. Extraintestinal pathogenic Escherichia coli: An update on antimicrobial resistance, laboratory diagnosis and treatment. Expert Rev. Anti Infect. Ther. 2012, 10, 1165-1176.
62. Paterson, D. L. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am. J. Med. 2006, 119, S20-S28.
63. Kirchner, M.; Wearing, H.; Teale, C. Plasmid-mediated quinolone resistance gene detected in Escherichia coli from cattle. Vet. Microbiol. 2011, 148, 434-435.
64. Snow, L. C.; Warner, R. G.; Cheney, T.; Wearing, H.; Stokes, M.; Harris, K.; Teale, C. J.; Coldham, N. G. Risk factors associated with extended spectrum beta-lactamase Escherichia coli (CTX-M) on dairy farms in North West England and North Wales. Prev. Vet. Med. 2012, 106, 225-234.
65. Platell, J. L.; Johnson, J. R.; Cobbold, R. N.; Trott, D. J. Multidrug-resistant extraintestinal pathogenic Escherichia coli of sequence type ST131 in animals and foods. Vet. Microbiol. 2011, 153, 99-108.
66. Hendriksen, R. S.; Mevius, D. J.; Schroeter, A.; Teale, C.; Jouy, E.; Butaye, P.; Franco, A.; Utinane, A.; Amado, A.; Moreno, M.; et al. Occurrence of antimicrobial resistance among bacterial pathogens and indicator bacteria in pigs in different European countries from year 2002-2004: The ARBAO-II study. Acta Vet. Scand. 2008, 50, 19.
67. Giufrè, M.; Graziani, C.; Accogli, M.; Luzzi, I.; Busani, L.; Cerquetti, M.; Escherichia coli Study Group. Escherichia coli of human and avian origin: Detection of clonal groups associated with fluoroquinolone and multidrug resistance in Italy. J. Antimicrob. Chemother. 2012, 67, 860-867.
68. Cengiz, M.; Buyukcangaz, E.; Arslan, E.; Mat, B.; Sahinturk, P.; Sonal, S.; Gocmen, H.; Sen, A. Molecular characterisation of quinolone resistance in Escherichia coli from animals in Turkey. Vet. Rec. 2012, 171, 151-154.
69. Aleisa, A. M.; Ashgan, M. H.; Alnasserallah, A. A.; Mahmoud, M. H.; Moussa, I. M. Molecular detection of β-lactamases and aminoglycoside resistance genes among Escherichia coli isolates recovered from medicinal plant. Afr. J. Microbiol. Res. 2013, 7, 2305-2310.
70. Gonzalez-Zorn, B.; Escudero, J. A. Ecology of antimicrobial resistance: Humans, animals, food and environment. Int. Microbiol. 2012, 15, 101-109.
71. Da Costa, P. M.; Loureiro, L.; Matos, A. J. Transfer of multidrug-resistant bacteria between intermingled ecological niches: The interface between humans, animals and the environment. Int. J. Environ. Res. Public Health 2013, 10, 278-294.
72. Korzeniewska, E.; Korzeniewska, A.; Harnisz, M. Antibiotic resistant Escherichia coli in hospital and municipal sewage and their emission to the environment. Ecotoxicol. Environ. Saf. 2013, 91, 96-102.
73. Bedenic, B.; Vranes, J.; Hofmann-Thiel, S.; Tonkic, M.; Novak, A.; Bucevic-Popovic, V.; Hoffmann, H. Characterization of the extended-spectrum beta-lactamases and determination of the virulence factors of uropathogenic Escherichia coli strains isolated from children. Wien. Klin. Wochenschr. 2012, 124, 504-515.
74. Dedeic-Ljubovic, A.; Hukic, M.; Bekic, D.; Zvizdic, A. Frequency and distribution of diarrhoeagenic Escherichia coli strains isolated from pediatric patients with diarrhoea in Bosnia and Herzegovina. Bosn. J. Basic Med. Sci. 2009, 9, 148-155.
75. Coban, A. Y.; Nohut, O. K.; Tanriverdi Cayci, Y.; Bayramoglu, G.; Pirincciler, M.; Cetinkaya, E.; Cekic Cihan, C.; Bozdogan, B.; Durupinar, B. Investigation of plasmid-mediated quinolone resistance determinants in enterobacteriaceae: A multicenter study. Mikrobiyol. Bul. 2012, 46, 366-374.
76. Karch, H.; Denamur, E.; Dobrindt, U.; Finlay, B. B.; Hengge, R.; Johannes, L.; Ron, E. Z.; Tonjum, T.; Sansonetti, P. J.; Vicente, M. The enemy within us: Lessons from the 2011 European Escherichia coli O104: H4 outbreak. EMBO Mol. Med. 2012, 4, 841-848.
77. Marejkova, M.; Rohacova, H.; Reisingerova, M.; Petras, P. An imported case of bloody diarrhea in the Czech Republic caused by a hybrid enteroaggregative hemorrhagic Escherichia coli (EAHEC) O104: H4 strain associated with the large outbreak in Germany, May 2011. Folia Microbiol. 2012, 57, 85-89.
78. Bielaszewska, M.; Mellmann, A.; Bletz, S.; Zhang, W.; Kock, R.; Kossow, A.; Prager, R.; Fruth, A.; Orth-Holler, D.; Marejkova, M.; et al. Enterohemorrhagic Escherichia coli O26: H11/H-: A new virulent clone emerges in Europe. Clin. Infect. Dis. 2013, 56, 1373-1381.
79. Markovska, R.; Schneider, I.; Ivanova, D.; Keuleyan, E.; Stoeva, T.; Sredkova, M.; Markova, B.; Bojkova, K.; Gergova, R.; Bauernfeind, A.; et al. High prevalence of CTX-M-15-producing O25b-ST131 Escherichia coli clone in Bulgarian hospitals. Microb. Drug Resist. 2012, 18, 390-395.
80. Boyer-Mariotte, S.; Duboc, P.; Bonacorsi, S.; Lemeland, J. F.; Bingen, E.; Pinquier, D. CTX-M-15-producing Escherichia coli in fatal neonatal meningitis: Failure of empirical chemotherapy. J. Antimicrob. Chemother. 2008, 62, 1472-1474.
81. Mielke, M. Prevention and control of nosocomial infections and resistance to antibiotics in Europe-Primum non-nocere: Elements of successful prevention and control of healthcare-associated infections. Int. J. Med. Microbiol. 2010, 300, 346-350.
82. Global Strategy for Containment of Antimicrobial Resistance; World Health Organization: Geneva, Switzerland, 2001.
83. Seib, K. L.; Zhao, X.; Rappuoli, R. Developing vaccines in the era of genomics: A decade of reverse vaccinology. Clin. Microbiol. Infect. 2012, 18, 109-116.
84. Gillings, M. R. Evolutionary consequences of antibiotic use for the resistome, mobilome and microbial pangenome. Front. Microbiol. 2013, 4, 4.
85. De Vrese, M.; Schrezenmeir, J. Probiotics, prebiotics, and synbiotics. Adv. Biochem. Eng. Biotechnol. 2008, 111, 1-66.
86. Preidis, G. A.; Hill, C.; Guerrant, R. L.; Ramakrishna, B. S.; Tannock, G. W.; Versalovic, J. Probiotics, enteric and diarrheal diseases, and global health. Gastroenterology 2011, 140, 8-14.
87. Mennigen, R.; Bruewer, M. Effect of probiotics on intestinal barrier function. Ann. N. Y. Acad. Sci. 2009, 1165, 183-189.
88. Amdekar, S.; Singh, V.; Singh, D. D. Probiotic therapy: Immunomodulating approach toward urinary tract infection. Curr. Microbiol. 2011, 63, 484-490.
89. Tobias, J.; Svennerholm, A. M. Strategies to overexpress enterotoxigenic Escherichia coli (ETEC) colonization factors for the construction of oral whole-cell inactivated ETEC vaccine candidates. Appl. Microbiol. Biotechnol. 2012, 93, 2291-2300.
90. Isidean, S. D.; Riddle, M. S.; Savarino, S. J.; Porter, C. K. A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression. Vaccine 2011, 29, 6167-6178.
91. Brumbaugh, A. R.; Mobley, H. L. Preventing urinary tract infection: Progress toward an effective Escherichia coli vaccine. Expert Rev. Vaccines 2012, 11, 663-676.
92. Moriel, D. G.; Bertoldi, I.; Spagnuolo, A.; Marchi, S.; Rosini, R.; Nesta, B.; Pastorello, I.; Corea, V. A.; Torricelli, G.; Cartocci, E.; et al. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc. Natl. Acad. Sci. USA 2010, 107, 9072-9077.
93. Nikaido, H. Multidrug resistance in bacteria. Annu. Rev. Biochem. 2009, 78, 119-146.
94. Worthington, R. J.; Melander, C. Combination approaches to combat multidrug-resistant bacteria. Trends Biotechnol. 2013, 31, 177-184.
95. Haq, I. U.; Chaudhry, W. N.; Akhtar, M. N.; Andleeb, S.; Qadri, I. Bacteriophages and their implications on future biotechnology: A review. Virol. J. 2012, 9, 9.
96. Fjell, C. D.; Hiss, J. A.; Hancock, R. E.; Schneider, G. Designing antimicrobial peptides: Form follows function. Nat. Rev. Drug Discov. 2012, 11, 37-51.
97. Parisien, A.; Allain, B.; Zhang, J.; Mandeville, R.; Lan, C. Q. Novel alternatives to antibiotics: Bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J. Appl. Microbiol. 2008, 104, 1-13.
98. Kutateladze, M.; Adamia, R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010, 28, 591-595.
99. Abedon, S. T.; Kuhl, S. J.; Blasdel, B. G.; Kutter, E. M. Phage treatment of human infections. Bacteriophage 2011, 1, 66-85.
100. Sulakvelidze, A.; Alavidze, Z.; Morris, J. G., Jr. Bacteriophage therapy. Antimicrob. Agents Chemother. 2001, 45, 649-659.
101. Brüssow, H. Phage therapy: The Escherichia coli experience. Microbiology 2005, 151, 2133-2140.
102. Maura, D.; Galtier, M.; Le Bouguenec, C.; Debarbieux, L. Virulent bacteriophages can target O104: H4 enteroaggregative Escherichia coli in the mouse intestine. Antimicrob. Agents Chemother. 2012, 56, 6235-6242.
103. Tsonos, J.; Adriaenssens, E. M.; Klumpp, J.; Hernalsteens, J. P.; Lavigne, R.; de Greve, H. Complete genome sequence of the novel Escherichia coli phage phAPEC8. J. Virol. 2012, 86, 13117-13118.
104. Chibeu, A.; Lingohr, E. J.; Masson, L.; Manges, A.; Harel, J.; Ackermann, H. W.; Kropinski, A. M.; Boerlin, P. Bacteriophages with the ability to degrade uropathogenic Escherichia coli biofilms. Viruses 2012, 4, 471-487.
105. Sillankorva, S. M.; Oliveira, H.; Azeredo, J. Bacteriophages and their role in food safety. Int. J. Microbiol. 2012, 2012, 863945, doi: 10. 1155/2012/863945.
106. Merabishvili, M.; de Vos, D.; Verbeken, G.; Kropinski, A. M.; Vandenheuvel, D.; Lavigne, R.; Wattiau, P.; Mast, J.; Ragimbeau, C.; Mossong, J.; et al. Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104: H4 strain from the 2011 outbreak in Germany. PLoS One 2012, 7, e52709, doi: 10. 1371/journal. pone. 0052709.
107. Doolittle, M. M.; Cooney, J. J.; Caldwell, D. E. Lytic infection of Escherichia coli biofilms by bacteriophage T4. Can. J. Microbiol. 1995, 41, 12-18.
108. Lacroix-Gueu, P.; Briandet, R.; Leveque-Fort, S.; Bellon-Fontaine, M. N.; Fontaine-Aupart, M. P. In situ measurements of viral particles diffusion inside mucoid biofilms. C. R. Biol. 2005, 328, 1065-1072.
109. Johnson, R. P.; Gyles, C. L.; Huff, W. E.; Ojha, S.; Huff, G. R.; Rath, N. C.; Donoghue, A. M. Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs. Anim. Health Res. Rev. 2008, 9, 201-215.
110. Li, H.; Ma, M. L.; Xie, H. J.; Kong, J. Biosafety evaluation of bacteriophages for treatment of diarrhea due to intestinal pathogen Escherichia coli 3-2 infection of chickens. World J. Microbiol. Biotechnol. 2012, 28, 1-6.
111. Rangel, J. M.; Sparling, P. H.; Crowe, C.; Griffin, P. M.; Swerdlow, D. L. Epidemiology of Escherichia coli O157: H7 outbreaks, United States, 1982-2002. Emerg. Infect. Dis. 2005, 11, 603-609.
112. Niu, Y. D.; Stanford, K.; Kropinski, A. M.; Ackermann, H. W.; Johnson, R. P.; She, Y. M.; Ahmed, R.; Villegas, A.; McAllister, T. A. Genomic, proteomic and physiological characterization of a T5-like bacteriophage for control of Shiga toxin-producing Escherichia coli O157: H7. PLoS One 2012, 7, e34585, doi: 10. 1371/journal. pone. 0034585.
113. Fischetti, V. A. Bacteriophage endolysins: A novel anti-infective to control Gram-positive pathogens. Int. J. Med. Microbiol. 2010, 300, 357-362.
114. Rodriguez-Rubio, L.; Martinez, B.; Donovan, D. M.; Rodriguez, A.; Garcia, P. Bacteriophage virion-associated peptidoglycan hydrolases: Potential new enzybiotics. Crit. Rev. Microbiol. 2013, 39, 427-434.
115. Hassan, M.; Kjos, M.; Nes, I. F.; Diep, D. B.; Lotfipour, F. Natural antimicrobial peptides from bacteria: Characteristics and potential applications to fight against antibiotic resistance. J. Appl. Microbiol. 2012, 113, 723-736.
116. Pande, J.; Szewczyk, M. M.; Grover, A. K. Phage display: Concept, innovations, applications and future. Biotechnol. Adv. 2010, 28, 849-858.
117. Lung, F. D.; Wang, K. S.; Liao, Z. J.; Hsu, S. K.; Song, F. Y.; Liou, C. C.; Wu, Y. S. Discovery of potent antimicrobial peptide analogs of Ixosin-B. Bioorg. Med. Chem. Lett. 2012, 22, 4185-4188.
118. Pini, A.; Giuliani, A.; Falciani, C.; Runci, Y.; Ricci, C.; Lelli, B.; Malossi, M.; Neri, P.; Rossolini, G. M.; Bracci, L. Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification. Antimicrob. Agents Chemother. 2005, 49, 2665-2672.
119. Corrales-Garcia, L.; Ortiz, E.; Castaneda-Delgado, J.; Rivas-Santiago, B.; Corzo, G. Bacterial expression and antibiotic activities of recombinant variants of human beta-defensins on pathogenic bacteria and M. tuberculosis. Protein Expr. Purif. 2013, doi: 10. 1016/j. pep. 2013. 02. 007.
120. Lira, F.; Perez, P. S.; Baranauskas, J. A.; Nozawa, S. R. Synthetic peptides antimicrobial activity prediction using decision tree model. Appl. Environ. Microbiol. 2013, 79, 3156-3159.
121. Tamma, P. D.; Cosgrove, S. E.; Maragakis, L. L. Combination therapy for treatment of infections with gram-negative bacteria. Clin. Microbiol. Rev. 2012, 25, 450-470.
122. Peleg, A. Y.; Hooper, D. C. Hospital-acquired infections due to gram-negative bacteria. N. Engl. J. Med. 2010, 362, 1804-1813.
123. Schweizer, H. P. Understanding efflux in Gram-negative bacteria: Opportunities for drug discovery. Expert Opin. Drug Discov. 2012, 7, 633-642.
124. Piddock, L. J. V. Multidrug-resistance efflux pumps-Not just for resistance. Nat. Rev. Microbiol. 2006, 4, 629-636.
125. Bioterrorism Agents/Diseases in Centers for Disease Control and Prrevention. Available online: www. bt. cdc. gov/agent/agentlist-category. asp (accessed on 5 October 2013).
126. Anderson, P. D.; Bokor, G. Bioterrorism: Pathogens as weapons. J. Pharm. Pract. 2012, 25, 521-529.
127. Masterton, R. The importance and future of antimicrobial surveillance studies. Clin. Infect. Dis. 2008, 47, S21-S31.